SweetFreedom is a research-community initiative building a structured framework to test a precise and consequential hypothesis:

This is not a commercial venture.
This is not a supplement initiative.
This is a disciplined, governance-backed, physician-supervised attempt to test whether the assumption of irreversibility was accepted too soon.

We are looking for partners willing to take that question seriously.

---

The Gap We Fill

For decades, Type 1 Diabetes research has pursued three primary strategies: immune suppression, preservation of remaining beta-cell function, and replacement of lost beta cells. Each has been studied in isolation.

One hypothesis has never been tested in a structured human pilot: that cell regeneration fails not because it is impossible, but because it is attempted within a chronically hostile biological environment.

SweetFreedom does not compete with the major research funders (JDRF, Helmsley, Breakthrough T1D) – it complements them. They fund excellent science, but within the constraints of the existing structure: single-PI studies, one intervention at a time. We test the integrated, multi-factorial hypothesis that emerges from the past decade’s converging findings – one those structures cannot fund. This is the gap a mission-driven philanthropic framework can fill.

---

Four Converging Mechanisms

The past decade has produced findings that reframe what the disease is. Type 1 Diabetes is no longer understood as a single immune event, but as the convergence of several mutually reinforcing processes:

• Microbiome dysbiosis: The TEDDY study (Nature, 2018) documented loss of SCFA-producing capacity in children’s guts, months before the first signs of autoimmunity. The dysbiosis precedes the disease.
• Persistent viral presence: The nPOD-Virus Group (2025) found enteroviral markers in 58.4% of T1D pancreases with islets still containing insulin, versus 17.8% in controls. A chronic, smoldering infection, not an acute one.
• Beta cells as active participants: Roep et al. (Nature Reviews Endocrinology, 2021) reframed beta cells – not as passive victims, but as active participants in their own destruction, through cytokine response, ER stress, and neo-epitope presentation.
• Beta cells can regenerate: Rosselot et al. (Science Translational Medicine, 2024) demonstrated a significant increase in human beta cell mass within three months, combining harmine and GLP-1. The dogma that adult beta cells cannot proliferate has been overturned.

Each finding has been pursued as an isolated direction. None has produced a breakthrough clinical result. Our hypothesis: this is because each addresses one component of a system that requires integrated, sequential restoration.

The SweetFreedom hypothesis: Regenerative interventions may only succeed if the cellular environment is restored first. Any other attempt is like trying to rebuild a house while it is still on fire.

---

The Sequential Restoration Model

If biological stress sustains dysfunction, then restoration must follow order. Each phase is biomarker-driven: progression is conditional upon measurable biological shift, not fixed timelines.

---

Where We Stand Today

• Protocol architecture: Complete (v4.3), with four phases and biomarker verification gates.
• First implementation: One family currently active, with full biomarker tracking.
• Scientific foundation: Comprehensive evidence synthesis based on 8 cohort studies and 80+ primary sources.
• Research dialogues: Dr. Eliana Mariño (Monash) – meeting completed; Prof. Marianna Rachmiel (Shamir Medical Center) – meeting completed; Dr. Tommi Vatanen (TEDDY) – meeting June 2026; Prof. Bart Roep (Leiden) – in coordination.
• Operational infrastructure: Active under the Israel Gives Fund (tax-deductibility in the US, UK, Canada, Australia, France, and Israel). Active partnerships with NordicLabs (Copenhagen) and EcoSupp (Israel).

---

Roadmap: From Foundation to Paradigm

The 18-month foundation phase is the first chapter of a longer arc. We share these milestones not as guarantees, but as a map of the destination we are working toward.

Foundation – Years 1-2

• Registered nonprofit with a medical board
• First two publications (mechanism paper, case series interim)
• Principal Investigator under contract
• Phase 2a protocol in the regulatory pipeline
• First major foundation grant (€450K-€1.8M)
• Case series cohort: 5-10 families with 12-month aggregated data

First Trial & Inflection – Years 3-5

• Phase 2a trial active (n=20-60, 18-24 month treatment)
• Primary publication in a leading journal (Diabetes / Diabetologia / Lancet D&E)
• Cumulative capital raised: €5M-€10M
• First SweetFreedom Center opens in clinical-pilot mode

Scale-up & Validation – Years 6-8

• Phase 2b multi-center trial (2-4 sites, n=120-200, randomized control)
• Cumulative capital raised: €20M-€50M
• 2-3 SweetFreedom Centers operational

Paradigm – Years 9-10

• Phase 3 trial active (multi-site, multi-country, n=400+)
• Protocol entering functional medicine guidelines
• 5-7 SweetFreedom Centers globally
• 1,000+ families through documented protocol implementation

Probability assessment: ~70% of reaching Year 2 milestones; ~50% of reaching the Year 5 inflection point; ~20-30% of the full Year 10 trajectory. Each milestone achieved substantially raises the probability of the next.

---

Partnership & Funding Tracks

Different scales of capital enable different stages of the roadmap. The first-year fundraising target stands at €150K-€220K – operational budget for Year 1, covering founder salary, operations, lab testing for the case series cohort, and first professional hires.

Track	Commitment	What It Enables
Community Partner	€25-€400 / month	Operational continuity. Community-tier supporters sustain the research framework and receive regular updates.
Research Partner	€500-€1,200 / month	Mid-tier supporters. Includes a microbiome test for the supporter, direct engagement with research findings, and quarterly briefings.
Anchor Partner	€2,000-€2,500 / month	Founder-level engagement. Four to five anchor partners cover the founder’s salary and operational base. Includes direct quarterly conversations with the founder and full data access.
Major Gift	€45,000-€230,000	Funds a defined component of the 18-month plan: case series infrastructure, regulatory consulting, biostatistical analysis, or PI retention. Named recognition where appropriate.
Foundation Grant	€450,000-€1,800,000	Funds Phase 2a setup, regulatory submission, and the first year of execution. Targeted at international T1D foundations (Helmsley, Bukhman, Breakthrough T1D, EFSD).

The ask: 4-6 founding partners for Year 1, through Anchor Partner commitments, Major Gifts, and catalytic introductions to foundations and senior researchers.

---

Three Open Questions

We are transparent about the dependencies the entire plan rests on – where credibility, capital, and time converge, and where a partner’s involvement is most valuable.

• The Principal Investigator: A qualified PI is essential for any formal trial. We are exploring three channels: existing clinical relationships, the Israeli functional medicine network, and Tier 2 researcher referrals.
• The Hospital Partnership: We are in discussions with a private hospital in southern Portugal as a potential trial site. Alternative pathways exist in Israel and at academic medical centers in Europe.
• The Scientific Advisory Board: We are building toward a scientific advisory board of 3-5 senior researchers. Conversations are open; formal commitments are still in process.

---

Transparency & Boundaries

• SweetFreedom is not a substitute for conventional medicine and does not compete with it
• There is no promise of a cure
• There is no personal treatment advice
• All work is conducted within ethical and clinical frameworks, under physician supervision

---

The Next Step

We invite you to a conversation to explore the possibility of partnership. We would value the opportunity to present the full scientific dossier, pilot architecture, governance plan, and partnership structure.

If this question deserves to be tested seriously, we are ready.